<DOC>
	<DOCNO>NCT01098591</DOCNO>
	<brief_summary>Numerous human cardiac stem cell study publish , include relatively small number patient . Meta-analysis randomized trial report safety 3-6 % increase global leave ventricular performance intracoronary stem cell therapy patient acute myocardial infarction . Since study use different type stem cell , delivery mode , patient population , result heterogenous , therefore comparison result bias regard generalizable conclusion effect treatment . The present comparative meta-analysis base individual patient data , gather pool raw data , analyze clinical outcome , safety efficacy cardiac stem cell therapy .</brief_summary>
	<brief_title>Meta-Analysis Cell-based CaRdiac stUdiEs : ACCRUE</brief_title>
	<detailed_description>- Background : Many clinical trial meta-analyses present moderate significant improvement leave ventricular ejection fraction ( LVEF ) intracoronary autologous bone-marrow ( BM ) peripheral blood origin stem cell transfer . However , remain controversial , whether beneficial effect comparable intramyocardial delivery stem cell , could maintain moderate long term follow-up . The BOOST trial suggest cardiac stem cell therapy improve LVEF 5-year follow-up . By contrast , BALANCE study show long sustained benefit BM-stem cell treatment . Due divergent outcome present trial , aim present meta-analysis compare safety effectiveness cardiac stem cell therapy different patient population , delivery mode cell type , find , patient therapy mode great benefit cardiac stem cell therapy . - Study design : individual patient data meta-analysis - Data source : European Centre perform human cardiac stem cell therapy contact call participation . - Methods : Individual data gather enter database pool analysis . The meta-analysis do line recommendation Cochrane Collaboration Quality Reporting Meta-analyses guideline Review Manager 5.0 . Fixed-effect model use .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>patient include one register cellbased cardiac therapy participate center</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>meta-analysis</keyword>
	<keyword>stem cell</keyword>
	<keyword>cardiac</keyword>
	<keyword>remodel</keyword>
	<keyword>MESS</keyword>
</DOC>